



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1617

Patent Application of

Richard B. Mazess

Application No. 09/995,911

Confirmation No.: 4126

Filed: November 28, 2001

Examiner: Criares, Theodore

I, Sally J. Sorensen, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Sally Sorensen
Signature

November 19, 2003
Date of Signature

RECEIVED

DEC 02 2003

TECH CENTER 1600/2

TREATMENT OF HYPERPROLIFERATIVE
DISEASES USING ACTIVE VITAMIN D
ANALOGUES

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B. Copies of the references are attached. This Statement is also being accompanied by a check in payment of the \$180.00 fee required under 37 CFR §1.17(p). Please charge or credit Deposit Account No. 50-0842 with any shortage or overpayment of the required fee. Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,

Jeffrey D. Peterson
Jeffrey D. Peterson
Reg. No. 49,038

11/23/2003 8828421 00000015 09995911

09 1741306


180.00 09

File No. 017620-9335

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
(608) 257-3501

Q:\client\017620\9335\B0267614.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	09/995,911
		Filing Date	November 28, 2001
		First Name Inventor	Mazess et al.
		Group Art Unit	1617
		Examiner Name	Theodore J. Criares
		Attorney Docket Number	017620-9335
1	of	1	

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------


	BA	4,160,803	Potts	07/10/79
	BB	4,717,721	DeLuca et al.	01/25/88
	BC	4,902,481	Clark et al.	02/20/90
	BD	5,141,719	Fernwood et al.	08/25/92
	BE	5,205,989	Aysta	04/27/93
	BF	5,219,528	Clark	06/15/93
	BG	5,232,836	Bouillon et al.	08/03/93
	BH	5,264,184	Aysta et al.	11/23/93
	BI	5,264,618	Felgner et al.	11/23/93
	BJ	5,334,740	Takahashi et al.	08/02/94
	BK	5,338,532	Tomalia et al.	08/16/94
	BL	5,417,923	Bojanic et al.	05/23/95
	BM	5,527,524	Tomalia et al.	06/18/96
	BN	5,554,386	Groman et al.	09/10/96
	BO	5,597,575	Breitbarth	01/28/97
	BP	5,614,513	Knutson et al.	03/25/97
	BQ	5,637,742	Valles et al.	06/10/97
	BR	5,661,025	Szoka, Jr. et al.	08/26/97
	BS	5,691,328	Peterson et al.	11/25/97

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 1				Complete if Known	
				Application Number	09/995,911
				Filing Date	November 28, 2001
				First Name Inventor	Mazess et al.
				Group Art Unit	1617
				Examiner Name	Theodore J. Criares
				Attorney Docket Number	017620-9335

RECEIVED
DEC 02 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
	BT	5,739,271	Sridhar et al.	04/14/98
	BU	5,795,882	Bishop et al.	08/18/98
	BV	5,798,345	Knutson et al.	08/25/98
	BW	6,503,893	Bishop et al.	01/07/03
	BX	6,521,608	Henner et al.	02/18/03
	BY	6,537,982	Bishop et al.	03/25/03
	BZ	6,538,037	Bishop et al.	03/25/03

FOREIGN PATENT DOCUMENTS

Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	CA	Japan	5320127	Nisshin Flour Milling Co.	09/29/93		
	CB	Japan	6025039	Kurary Co. Ltd.	02/01/94		
	CC	Japan	62000033	General Hospital	10/15/86		
	CD	PCT	WO 93/07883	ISIS Pharmaceuticals	04/29/93		


Q:\client\017620\9335\B0265972.1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/995,911	
			Filing Date	November 28, 2001	
			First Named Inventor	Mazess et al.	
			Group Art Unit	1617	
			Examiner Name	Theodore J. Criares	
Sheet	1	of	2	Attorney Docket Number	017620-9335

RECEIVED
DEC 02 2003
TECH CENTER 1600/2900


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

CE	Beer, T. et al., "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
CF	Blazsek, I. et al. "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 α ,25 Dihydroxyvitamin D ₃ , and Prednisone," 16:4:259-264 (Abstract).
CG	Carter, Stephen K. et al. <i>Chemotherapy of Cancer</i> 2 nd Ed. (1981) 362-365.
CH	Cho, Y.L. et al., "Combined Effects of 1,25-Dihydroxyvitamin D ₃ and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
CI	Defacque, H. et al., "Different Combinations of Retinoids and Vitamin D ₃ Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
CJ	Endo, K. et al., "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
CK	Hershberger, P. et al. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
CL	Johnson, C. et al., "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
CM	<i>Journal of Bone and Mineral Research</i> , (1994) 9:5:607-614.
CN	Kim, S. et al., "Potentiation of 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone," <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
CO	Londowski, J.M. et al., "Biological Activity of the C-1, C-3, C-25, β -D-Glucopyranosides of 1,25-Dihydroxyvitamin D ₃ ," <i>J. Pharmacology Expt. Ther.</i> , (1986) 237:3:837-840.
CP	Mathias, C.J. et al., "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.
CQ	Moffatt, K. et al., "1 α ,25-Dihydroxyvitamin D ₃ and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.
CR	Muindi, J. et al., "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology & Therapeutics</i> , (Dec. 2002) pp. 648-659.

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
			Application Number	09/995,911	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	November 28, 2001	
			First Named Inventor	Mazess et al.	
			Group Art Unit	1617	
			Examiner Name	Theodore J. Criares	
			Attorney Docket Number	017620-9335	
Sheet	2	of	2		

RECEIVED
DEC 02 2003
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	CS	Packman, K. et al. "Combination Treatment of MCF-7 Xenografts with the Vitamin D ₃ Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.
	CT	Ravid, A. et al., "1,25-Dihydroxyvitamin D ₃ Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.
	CU	Siwinska, A. et al. "Potentiation of the Antiproliferative Effect <i>in Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.
	CV	Slapak, C. et al., "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
	CW	Song, X.D. et al., "Bryostatins-1 and 1 α ,25-Dihydroxyvitamin D ₃ Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
	CX	Studzinski, G. et al., "Potentiation by 1- α ,25-Dihydroxyvitamin D ₃ of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
	CY	Suzuki, Y. et al., "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
	CZ	Swami, S. et al. "1 α ,25-Dihydroxyvitamin D ₃ Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
	DA	Torres, R. et al., "Etoposide Stimulates 1,25-Dihydroxyvitamin D ₃ Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells," <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
	DB	Wang, Q. et al., "1,25-Dihydroxyvitamin D ₃ and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
	DC	Wang, X. et al., "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
	DD	Yu, W. et al., "Enhancement of 1,25-Dihydroxyvitamin D ₃ - Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.

Q:\client\017620\9335\B0265973.1

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.